Enterprise Bank & Trust Co Raises Stock Holdings in GSK plc (NYSE:GSK)

Enterprise Bank & Trust Co raised its position in shares of GSK plc (NYSE:GSKFree Report) by 14.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,257 shares of the pharmaceutical company’s stock after purchasing an additional 3,219 shares during the quarter. Enterprise Bank & Trust Co’s holdings in GSK were worth $936,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GSK. Fairfield Bush & CO. bought a new position in GSK in the 1st quarter worth approximately $80,000. JPMorgan Chase & Co. raised its holdings in shares of GSK by 2.3% during the 1st quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock worth $10,514,000 after acquiring an additional 5,518 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in GSK during the 1st quarter valued at $467,000. Blair William & Co. IL raised its holdings in GSK by 3.0% during the 1st quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock valued at $1,620,000 after buying an additional 1,094 shares during the period. Finally, Cetera Investment Advisers raised its holdings in GSK by 2.4% during the 1st quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock valued at $2,744,000 after buying an additional 1,453 shares during the period. 13.53% of the stock is currently owned by institutional investors.

GSK Stock Performance

GSK stock traded down $0.89 during trading on Friday, hitting $42.19. 4,130,059 shares of the company traded hands, compared to its average volume of 3,824,464. The stock’s 50-day simple moving average is $41.21 and its 200 day simple moving average is $37.94. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. The company has a market cap of $86.84 billion, a PE ratio of 14.02, a P/E/G ratio of 1.96 and a beta of 0.64. GSK plc has a 1 year low of $33.24 and a 1 year high of $43.84.

GSK (NYSE:GSKGet Free Report) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to analyst estimates of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, equities analysts expect that GSK plc will post 4.08 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd will be given a $0.3564 dividend. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a $1.43 dividend on an annualized basis and a yield of 3.38%. This is an increase from GSK’s previous quarterly dividend of $0.34. GSK’s payout ratio is currently 52.82%.

Analyst Ratings Changes

A number of analysts have weighed in on GSK shares. Morgan Stanley started coverage on GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Get Our Latest Stock Report on GSK

GSK Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.